Albireo reports inducement grant under nasdaq listing rule 5635(c)(4)

Boston, july 26, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today announced the grant of inducement restricted stock units to acquire 16, 200 shares of albireo's common stock. the restricted stock units were granted as an inducement material to the employee's acceptance of employment with albireo in accordance with nasdaq listing rule 5635(c)(4). the restricted stock units vest over a four-year period, subject to the employee's continued service with albireo through the applicable vesting dates. the vesting schedule for each restricted stock unit is 25 percent on the one-year anniversary of the employee's start date with albireo and 75 percent in 12 equal quarterly installments thereafter. the restricted stock units are subject to the terms and conditions of albireo's 2020 inducement equity incentive plan.
ALBO Ratings Summary
ALBO Quant Ranking